Outset Medical, Inc. (OM) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Outset Medical, Inc. (OM) Healthcare & Pipeline Overview

Outset Medical, Inc. pioneers the Tablo Hemodialysis System, a compact and integrated solution for dialysis care, targeting both acute and home settings. With its on-demand dialysate production and user-friendly design, Outset aims to improve the dialysis experience and expand access to care, operating within the competitive medical device landscape.

What Is the Investment Thesis for OM?

Outset Medical presents a compelling, yet high-risk, investment case centered on the potential of its Tablo Hemodialysis System to disrupt the dialysis market. The company's innovative technology offers a more flexible and user-friendly alternative to traditional dialysis methods, appealing to both acute care facilities and home users. Key value drivers include the expansion of Tablo's installed base, increased utilization rates, and the potential for recurring revenue through disposables and service contracts. However, the company's negative profit margin of -63.7% and substantial competition pose significant challenges. Growth catalysts include ongoing clinical trials, regulatory approvals for new applications, and strategic partnerships with healthcare providers. Success hinges on Outset's ability to scale production, manage costs, and effectively market its technology to a broad range of customers.

Based on FMP financials and quantitative analysis

OM Key Highlights

Market capitalization of $79.6M reflects the company's current valuation and investor sentiment.

• Gross margin of 40.6% indicates the profitability of Outset Medical's core product, the Tablo Hemodialysis System.
• The company operates with 354 employees, reflecting its scale and operational capacity.
• Beta of 1.96 suggests higher volatility compared to the overall market, indicating potential for significant price swings.
• The company does not offer a dividend, indicating a focus on reinvesting earnings for growth.

Who Are OM's Competitors?

OM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OM's Key Strengths?

Innovative Tablo Hemodialysis System with integrated features.

• User-friendly design suitable for both clinical and home settings.
• Potential to reduce costs and improve patient outcomes.
• Strong intellectual property portfolio.

What Are OM's Weaknesses?

Negative profit margin and ongoing losses.

• Limited market share compared to established competitors.
• Reliance on a single product line.
• High capital expenditure requirements.

What Could Drive OM Stock Higher?

Expansion of Tablo system placements in acute care facilities.

• Increased adoption of Tablo for home hemodialysis.
• Potential regulatory approvals for new Tablo system applications.
• Publication of clinical trial results demonstrating improved patient outcomes with Tablo.

What Are the Key Risks for OM?

Financial-distress signal — its Altman Z-Score of -6.08 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-55.9%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Competition from established dialysis providers with greater resources.
• Technological advancements by competitors that could render Tablo obsolete.
• Regulatory changes or unfavorable reimbursement policies that could impact adoption.
• Product liability claims related to the Tablo system.
• The company's current financial losses and need for additional funding.

What Are the Growth Opportunities for OM?

• Expansion into the home dialysis market represents a significant growth opportunity for Outset Medical. The home dialysis market is projected to grow substantially by 2028, driven by patient preference for greater autonomy and convenience. Tablo's user-friendly design and integrated features make it well-suited for home use, potentially capturing a significant share of this expanding market. Success depends on Outset's ability to navigate regulatory hurdles, establish effective training programs, and build a strong support network for home dialysis patients.
• Strategic partnerships with large hospital systems and dialysis clinics can accelerate the adoption of the Tablo system. By collaborating with established healthcare providers, Outset Medical can gain access to a broader customer base and leverage existing infrastructure. These partnerships can also provide valuable clinical data and feedback, further refining the Tablo system and enhancing its market appeal. Securing long-term contracts and demonstrating the economic benefits of Tablo are crucial for realizing this growth opportunity.
• Development of new applications for the Tablo system beyond traditional hemodialysis can unlock additional revenue streams. Potential applications include peritoneal dialysis, continuous renal replacement therapy (CRRT), and other fluid management therapies. Expanding the Tablo system's capabilities would broaden its addressable market and strengthen its competitive position. Successful development and regulatory approval of these new applications are essential for capitalizing on this growth opportunity.
• Geographic expansion into international markets represents a long-term growth opportunity for Outset Medical. The global dialysis market is vast, with significant unmet needs in many regions. By adapting the Tablo system to meet local regulatory requirements and cultural preferences, Outset Medical can tap into new customer segments and diversify its revenue base. Thorough market research, strategic partnerships with local distributors, and effective marketing campaigns are crucial for successful international expansion.
• Leveraging data analytics and connectivity features of the Tablo system to improve patient outcomes and reduce healthcare costs. The Tablo system generates a wealth of data on dialysis treatments, which can be analyzed to identify trends, optimize treatment protocols, and personalize care. By partnering with healthcare providers and researchers, Outset Medical can unlock the value of this data and demonstrate the economic and clinical benefits of its technology. Developing secure and compliant data sharing platforms is essential for realizing this growth opportunity.

What Are OM's Competitive Advantages?

• Proprietary technology: The Tablo Hemodialysis System's integrated design and on-demand dialysate production provide a unique competitive advantage.
• Regulatory approvals: Securing FDA clearance and other regulatory approvals creates a barrier to entry for competitors.
• Established customer relationships: Building strong relationships with hospitals, clinics, and home users fosters customer loyalty.
• Data and analytics: Leveraging the Tablo system's data connectivity to improve patient outcomes and reduce costs creates a valuable competitive advantage.

What Does OM Do?

Outset Medical, Inc., established in 2003 and headquartered in San Jose, California, is a medical technology company dedicated to transforming dialysis through innovative solutions. Originally named Home Dialysis Plus, Ltd., the company rebranded to Outset Medical, Inc. in January 2015 to reflect its broader mission. The company's flagship product is the Tablo Hemodialysis System, a comprehensive system designed for use in acute care settings, such as hospitals and clinics, as well as in the home. Tablo integrates water purification, on-demand dialysate production, and a user-friendly interface into a single, compact console. This all-in-one design aims to simplify the dialysis process, reduce the reliance on traditional infrastructure, and improve the patient experience. Outset Medical's focus on innovation and patient-centric design positions it as a key player in the evolving dialysis market, addressing the growing need for more flexible and accessible dialysis solutions. The company's technology aims to reduce costs, improve workflows, and enhance the overall quality of life for dialysis patients.

What Products and Services Does OM Offer?

• Develops the Tablo Hemodialysis System, an all-in-one dialysis solution.
• Integrates water purification, dialysate production, and system monitoring into a single console.
• Offers a user-friendly interface designed for both clinical and home settings.
• Provides on-demand dialysate production, reducing the need for external supplies.
• Offers connectivity capabilities for remote monitoring and data analysis.
• Aims to simplify the dialysis process and improve patient outcomes.

How Does OM Make Money?

• Sells the Tablo Hemodialysis System to hospitals, dialysis clinics, and home users.
• Generates recurring revenue through the sale of disposables, such as dialyzers and tubing sets.
• Provides service and maintenance contracts for the Tablo system.
• Potentially generates revenue through data analytics and remote monitoring services.

What Industry Does OM Operate In?

Outset Medical operates within the medical device industry, specifically targeting the dialysis market. This market is characterized by a growing prevalence of chronic kidney disease (CKD) and a demand for more convenient and cost-effective treatment options. Outset Medical's Tablo system competes with established players offering traditional dialysis machines and services, as well as emerging companies developing innovative dialysis technologies. The company's focus on integrated, user-friendly systems positions it to capitalize on the trend towards decentralized and home-based dialysis care.

Who Are OM's Key Customers?

• Hospitals and acute care facilities requiring dialysis equipment.
• Dialysis clinics and centers providing outpatient dialysis services.
• Individual patients who perform dialysis at home.
• Veterinary clinics requiring dialysis equipment for animals.

Company Profile

Outset Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in San Jose, US. The company is led by CEO Leslie L. Trigg. OM has traded publicly since 2020.

Outset Medical, Inc. Financial Trajectory

Outset Medical, Inc. (OM) reported $31.6M in revenue for Q2 2026, reflecting 13.5% growth compared to the prior quarter. The company recorded a net loss of $18.0M, with diluted EPS of $-0.97. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, OM averaged $-1.02 in diluted EPS.

How Outset Medical, Inc. Is Valued

Outset Medical, Inc. carries a market capitalization of $79.6M, placing it in the micro-cap category. Relative to its peer group, OM's quantitative score of 18/100 is below the peer average of 63/100.

Return on equity for Outset Medical, Inc. stands at -55.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -36.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.29 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -81.2%, the inverse of the P/E and a quick read on earnings relative to price.

Outset Medical, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.08 places it in the distress zone, a signal of elevated financial risk.

Outset Medical, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 203.4% below estimates on average.

Wall Street analysts project Outset Medical, Inc. revenue of about $125.7M for fiscal 2026, with EPS near $-2.91.

Over the past six months, Outset Medical, Inc. insiders filed 17 SEC Form 4 transactions — 4 sales and 13 purchases. On net that is roughly 983K shares acquired (about $3.0M) — insiders putting money in tends to read as conviction.

OM Financials

OM Latest News

OM Analyst Consensus

OM MoonshotScore

Common Questions About OM (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources